Background Skin and mucosal herpes simplex virus type 2 (HSV-2) shedding predominantly occurs in short subclinical episodes. We assessed whether standard-dose or high-dose antiviral therapy reduces the frequency of such shedding.
Introduction
Infection with herpes simplex virus type 2 (HSV-2) is a global epidemic, 1 and signifi cantly increases the risk of HIV-1 acquisition. 2 Despite the increased use of antiviral therapy in the past two decades, the prevalence of, and complications from, HSV-2 infection have changed little. 3, 4 Daily antiviral therapy reduces genital lesions 5, 6 and suppresses detection of HSV on genital mucosal surfaces (shedding). 7, 8 However, treatment with daily valaciclovir results in only a 48% reduction in the risk of sexual transmission. 9 Moreover, aciclovir does not eff ectively reduce the risk of HIV transmission or acquisition in HSV-2-seropositive people. [10] [11] [12] The discrepancy between potent suppression of clinical symptoms and failure of antiviral agents to fully prevent HSV transmission is not well understood.
Intensive genital secretion collection shows that HSV shedding episodes are three-times more frequent than was previously realised. 13 Nearly 50% of reactivations last less than 12 h; presumably they are cleared by the mucosal immune system. 13, 14 Mathematical models suggest that these short bursts of shedding are even more frequent than current sampling methods can detect, constituting 70-85% of all reactivations. 15 Local host immune responses seem to control the severity, duration, and amount of virus detected during an outbreak. 16 Trials using once daily genital sampling suggest that antiviral drugs reduce long episodes of high-copy-number HSV reactivation. 7 However, whether antiviral drugs suppress short reactivation events is unknown. Failure to do so could account for the lower than expected eff ectiveness of antiviral drugs in clinical studies of HSV-2 transmission.
We did three complementary clinical studies to assess whether either standard or high doses of aciclovir and valaciclovir aff ect the frequency of short, subclinical periods of HSV genital reactivation.
Methods

Patients
HSV-2-seropositive, HIV-seronegative healthy adults, aged 18 years or older were recruited at the University of Washington Virology Research Clinic between November, 2006, and July, 2010. In trial 1, patients with both symptomatic and asymptomatic genital herpes were recruited. In trials 2 and 3, participants needed to have had at least four clinical HSV-2 recurrences in the previous year or laboratory-documented primary genital HSV-2 in the previous 6 months. Participants with previous adverse reactions to aciclovir, pregnant women, and those unable to comply with study procedures were excluded. Participants were recruited through newspaper adver tisements, fl iers, and by word of mouth. The studies were approved by the University of Washington Human Subjects Division and all participants provided written, informed consent.
Randomisation and masking
The random treatment allocation sequence was generated by a study statistician (MS) with a computerised random number generator. The sequence was known only to the statistician and the pharmacist, who prepared sequentially numbered, identical, sealed boxes containing the study drug and the assignment of fi rst group in the crossover. Participants were assigned the next sequential sealed box by a study clinician at enrolment. Random isation was stratifi ed by sex. Patients were randomly assigned at a ratio of 1:1 for all drug groups. All three trials were open label, but clinical data were masked from laboratory personnel.
Procedures
Participants received the study medication for a prespecifi ed period, had a 1 week wash-out period, and then crossed over to the other study medication for the remaining study period (fi gure 1). Trial 1 was designed to test whether standard-dose aciclovir (400 mg twice daily) suppressed short subclinical episodes of HSV shedding compared with no medication. Each study period was for 4 weeks. Trials 2 and 3 assessed whether higher doses of antiviral drugs or changes in the dosing schedule could provide more potent suppression of short shedding episodes. Participants in trial 2-standard-dose valaciclovir (500 mg daily) versus high-dose aciclovir (800 mg three times daily)-were followed up for 7 weeks in each group. Participants in trial 3-standard-dose versus high-dose valaciclovir (1 g three times daily) were followed up for 5 weeks in each group. The high doses were selected to provide a two-to-three times (for highdose aciclovir) 6, 17 and an eight times (for high-dose valaciclovir) 17 was selected because clinical data suggest that this dose is safe. The study period was longer in trials 2 and 3 because we expected shedding rates during antiviral therapy to be low and we needed suffi cient power to detect small diff erences in shedding rates between the two groups.
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Participants self-collected one genital swab four times daily, about every 4-6 h while awake, during each study period. 13 Women swabbed the vaginal vault, the entire labia majora and labia minora, the perineum, and perianal area. Men swabbed the penile shaft, scrotum, perineum, and perianal area. Participants recorded genital symptoms and lesions daily. 19 Participants met a clinician once every 2 weeks for swab collection, medication administration, assessment of side-eff ects, and genital examination, if symptomatic.
HSV serostatus was tested by western blot. 20 Genital swabs were placed in 1 mL 1X PCR buff er and stored at 4°C. DNA was extracted from genital swabs, and HSV was quantifi ed by real-time PCR, with HSV-specifi c primers to glycoprotein B. 21 Samples containing 150 copies of HSV DNA or more per mL of PCR buff er were classed as positive. 22 The primary outcome was HSV shedding rate, measured by the number of swabs with HSV detected divided by the number of swabs collected during each treatment period per participant, for each study. Secondary outcomes by treatment group were number of HSV shedding episodes, duration of HSV shedding episodes, and maximum quantity of HSV DNA detected in a shedding episode. Episodes were defi ned as any number of swabs with HSV detected, immediately preceded by two negative swabs and followed by two negative swabs. Episode duration was extrapolated by estimation of start and stop times at the midpoint between the last HSVpositive and fi rst HSV-negative swabs. Participants who did not collect at least one swab during each study period were excluded from the analyses.
Adverse events were assessed at each study visit. White blood cell count, and renal and liver function tests were done once every 2 weeks in people enrolled in trial 3. Adverse events were graded with National Cancer Institute common terminology criteria (version 3.0).
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Statistical analysis
Estimates of shedding frequency were based on natural history studies using four samples per day, 13, 14 and withinperson correlation was estimated to be 0·2. 7 Use of a sample size calculation for repeated-measures binary data 24 and assumption of a genital shedding rate of 10% with no medication provides trial 1 with 80% power to detect a 35% reduction in genital shedding rates for standard-dose aciclovir. Assumption of a genital shedding rate of 3% for standard-dose valaciclovir 7 provides trials 2 and 3 with 80% power to detect a 50% reduction in HSV genital shedding rates for high-dose aciclovir or valaciclovir compared with standard-dose valaciclovir. A 20% loss to follow-up was assumed for all trials. The fi rst day in each treatment period was excluded from the analysis. HSV genital shedding rates and episode rates were compared by Poisson regression, including a scale parameter for overdispersion and the log number of swabs as the off set. Sequence and period eff ects were included in the model. Generalised estimating equations were used to compare shedding rates between no medication and drug groups in trials 2 and 3. Linear mixed models were used to compare episode rate, episode duration, maximum HSV log 10 copy number during episodes, and HSV log 10 copy number in positive swabs by treatment group, and to test for an association between episode duration and maximum HSV log 10 copy number. Episode kinetics were calculated by computation of the slope of a linear regression line from the beginning to peak (expansion) or peak to end (clearance) of an episode. 25 The Wilcoxon signed rank test for matched pairs was used to compare drug adherence rates by treatment as measured by pill counts. Correlation between adherence and genital shedding rate was measured with the Spearman correlation coeffi cient. The yearly episode rate was calculated by dividing the number of episodes by the person-years of follow-up per treatment group. Two-sided p values less than 0·05 were judged statis tically signifi cant. Data were analysed with Stata version 10.1. The trials are registered at ClinicalTrials.gov (NCT00362297, NCT00723229, NCT01346475).
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Of 157 participants screened, 90 were enrolled and took samples for both study periods (fi gure 1); three participants enrolled in both trial 1 and trial 3, so were excluded from the comparison of shedding rates between the no medication and drug groups. The median age was 43 years (IQR 30-51). 49 (54%) participants were women, and 76 (84%) were white. 50 (56%) participants were HSV-2 seropositive only; 39 (43%) were HSV-1 and HSV-2 seropositive. The median duration of HSV-2 infection was 7·6 years (IQR 1·8-19·5). The demo graphics of the study population were similar in each of the trials (webappendix).
90 participants took 23 605 (86%) of a possible 27 319 swabs. Swabs were taken a median of 5·8 h (IQR 4·5-7·2) apart. 23 participants took 2123 swabs while receiving no medication, and HSV was detected in 384 (18%) of these swabs (table, fi gure 2). Although all doses of aciclovir reduced the frequency of detection of HSV compared with no medication (no medication vs standard-dose valaciclovir, p=0·003; no medication vs See Online for webappendix high-dose aciclovir, p=0·002; no medication vs high-dose valaciclovir, p<0·0001), breakthrough reactivation occurred at all drug doses (fi gure 2). Fewer swabs had detectable HSV during standard-dose aciclovir compared with no medication (IRR 0·05, 95% CI 0·03-0·08). HSV detection was lower for high-dose aciclovir compared with standard-dose valaciclovir (table; IRR 0·79, 95% CI 0·63-1·00). A dose eff ect on HSV shedding was noted during high-dose valaciclovir compared with standarddose valaciclovir (table; IRR 0·54, 95% CI 0·44-0·66). No sequence eff ects were detected for any trial (webappendix). Period eff ects were present in all three trials and the models were adjusted accordingly.
In total, 344 genital HSV shedding episodes occurred (webappendix). The table shows characteristics of HSV shedding episodes by treatment group. Most shedding episodes were subclinical during all active treatment periods. Episodes were signifi cantly less frequent in patients receiving standard-dose aciclovir than in those receiving no medication (p=0·001). Episode frequency did not diff er between standard-dose valaciclovir and high-dose aciclovir (p=0·54), or between standard-dose and high-dose valaciclovir (p=0·34).
The median maximum number of HSV copies detected per episode was signifi cantly higher during no medication than with standard-dose aciclovir (table; p=0·02). The quantity of HSV detected did not diff er during episodes for standard-dose valaciclovir and highdose aciclovir (p=0·66), but it was signifi cantly lower for high-dose valaciclovir than for standard-dose valaciclovir (p=0·001). The distribution of quantity of HSV detected on each antiviral dose is shown in the webappendix.
Of the 344 HSV shedding episodes, 84 were of unknown duration; in 44 (13%) cases the episode was detected at the Maximum log 10 copies per mL
Data are n/N (%), n (%), or median (IQR) unless otherwise stated. HSV=herpes simplex virus. *The number of participants is as noted in fi gure 1, excluding those who were lost to follow-up. †Data missing for three episodes. ‡Data missing for 11 episodes.
Table: HSV shedding outcomes
Figure 2: HSV detection in genital swabs
Error bars are the 95% CIs. AUCs taken from Reitano and colleagues 6 and Beutner and colleagues. 17 IRR=incidence risk ratio. AUC=area under the curve (μg × h per mL).
beginning or end of the treatment period, and in 40 (12%) swabs were missing. Of the 260 HSV shedding episodes of known duration, median episode duration was longer with no medication than for standard-dose aciclovir (table; p=0·01). The median episode duration was the same for standard-dose valaciclovir and high-dose aciclovir (p=0·23), but it was signifi cantly shorter for highdose than for standard-dose valaciclovir (p=0·03). The median viral expansion in 6 h was much the same for standard-dose valaciclovir (4·6 log, IQR 1·5-5·7), highdose aciclovir (4·8 log, 1·5-5·5) and high-dose valaciclovir (4·7 log, 4·4-5·2). However, viral clearance in 6 h was greater for high-dose valaciclovir (4·7 log, 4·4-5·2) than for standard-dose valaciclovir (4·4 log, 0·8-4·7, p=0·016). Most shedding episodes on antiviral therapy were short irrespective of dose: 75 (60%) of 126 episodes with standard-dose antiviral therapy, 33 (58%) of 57 with highdose aciclovir, and 32 (78%) of 41 with high-dose valaciclovir lasted less than 12 h (webappendix). Episode duration was correlated with maximum log 10 copy number during the episode (0·15 log for each 6 h increase, p<0·0001). Demographic characteristics and shedding rates of participants who were lost to follow-up and those who completed the study did not diff er (webappendix). 78-96% of participants in each study reported more than 85% adherence to the study medication, with a median adherence of 98-100% for each study group. No correlation between drug adherence and shedding was detected (data not shown). 3748 swabs were missing for participants included in the fi nal analysis, which corresponds to 1630 intervals when at least one swab was not taken. Of these intervals, 1129 (69%) had a swab missing at one point, 410 (25%) were missing a swab at two to fi ve consecutive points, and 91 (6%) were missing swabs from more than fi ve consecutive timepoints. Each study group and trial had a similar proportion of missing swabs (11·4%, 14·3%, and 14·8% for trial 1, 2, and 3, respectively).
During high-dose valaciclovir therapy, 13 (30%) of 43 participants complained of headache on at least 1 day (compared with none for standard-dose valaciclovir). Nausea (n=3; 7%), and myalgias (n=2; 5%) were also reported during high-dose valaciclovir. Two (5%) participants developed grade 2 neutropenia with highdose and standard-dose valaciclovir. No additional abnormalities in complete blood count, liver function, or renal function, or adverse events related to study medication were noted. We sequenced the HSV thymidine kinase gene from a representative swab sample 26 of one participant with high rates of shedding in both study periods in trial 2 (webappendix), and did not detect any mutation known to confer aciclovir resistance (Genbank accession number HM446467).
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Discussion
Although daily antiviral therapy nearly eliminated symptomatic recurrences and reduced the frequency of episodes of shedding with high copy number, short episodes of genital HSV shedding occur frequently with antiviral therapy, even for high-dose regimens that increase the aciclovir AUC eight times compared with standard suppressive doses of aciclovir or valaciclovir. These breakthrough episodes are typically subclinical, last several hours, and occur at much the same rate irrespective of antiviral dose, providing a likely explanation for the inability of daily suppressive therapy to completely abrogate HSV-2 transmission.
Studies measuring the clinical eff ectiveness of aciclovir and valaciclovir in immunocompetent people have shown similar effi cacy, except in people with very frequent recurrences (panel). 6 Initial clinical trials of aciclovir and valaciclovir showed high effi cacy for the prevention of genital herpes symptomatic recurrences. 5, 6 Trials that assessed suppression of subclinical shedding also showed a substantial eff ect, although effi cacy was greater when measured by viral culture (roughly 95%) 8 than by PCR (70-80%). 7 Because of the high success in reduction of clinical and subclinical shedding, valaciclovir 500 mg daily was selected as the dose to test for reduction in sexual transmission of HSV. Interestingly, this dose reduced the sexual transmission of HSV by only 48% in discordant couples, despite a 73% reduction in subclinical shedding in the same population. 9 In our study, most participants had one or two shedding episodes per month with both standard-dose and high-dose antiviral therapy. Despite the
Panel: Research in context
Systematic review A meta-analysis 28 of 14 randomised clinical trials of antiviral therapy for herpes simplex virus type 2 (HSV-2) showed a 47% (95% CI 45-49) overall relative risk reduction of recurrence in patients receiving suppressive therapy compared with placebo. 28 Aciclovir and valaciclovir also suppress genital herpes shedding by 70-80% compared with placebo. 7 Suppression of genital herpes with aciclovir and valaciclovir has been studied for public health benefi t; to prevent both HSV-2 transmission, 9 and HIV transmission 12 and acquisition. 10, 11 Despite a 70% reduction in genital HSV-2 shedding, HSV-2 transmission was suppressed by only 48%. 9 Furthermore, HSV-2 suppression was not eff ective in preventing HIV transmission 12 or acquisition. 10, 11 These results have led to questions about the discrepancy between shedding rates and clinical outcomes, and whether increased doses of antiviral agents would be eff ective.
Interpretation
Our results show that short episodes of subclinical shedding persist with both standard-dose and high-dose aciclovir and valaciclovir. Although HSV shedding was reduced by 50% with the highest doses of valaciclovir (1 g, three times daily), the rate of breakthrough shedding episodes did not change-about 16-20 episodes per year. These data suggest that novel therapies are needed to completely prevent HSV reactivation.
valaciclovir, to better detect a diff erence in shedding rates between the study periods. Despite the attempt to show such a diff erence, even very high doses of valaciclovir were associated with breakthrough genital HSV shedding. The trials were done at a single site, and enrolled mostly white, healthy, sexually active adults. 33 The generalisability of these data to other geographic regions or racial or ethnic groups is unknown. Furthermore, we cannot extrapolate these fi ndings to immunosuppressed patients. Although the studies were open label, we do not expect that this introduced bias because the endpoint (HSV shedding) is not subjective and laboratory personnel were masked to study group.
Although currently available anti-HSV therapy benefi ts patients by preventing clinical HSV recurrences, suppressive therapies with greater potency, including antiviral drugs or immunotherapy in the form of therapeutic vaccines, are needed to provide substantial public health benefi ts, such as prevention of HSV-2 transmission and HIV-1 acquisition and transmission.
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short duration of these episodes, a substantial proportion-20% for standard-dose antiviral therapyhad more than 10⁴ HSV copies per mL; these episodes were not eliminated with high-dose valaciclovir. Our data suggest that anti-HSV therapy, although clinically eff ective, does not substantially alter the underlying pathobiology of frequent, subclinical HSV-2 reactivation. That we could not eliminate or even alter the frequency of shedding episodes with high-dose valaciclovir suggests that the maximum benefi t of shedding reduction has probably been reached for currently available antiviral drugs.
Modelling studies suggest that reported shedding patterns can be replicated by simulated frequent release of small amounts of HSV from neurons. 15 The short episodes noted in our trial might be the earliest HSV replication events during or after neuronal HSV reactivation. Possible explanations for this fi nding include inadequate aciclovir concentrations in neurons because of the blood-brain barrier 29 or less effi cient conversion to aciclovir triphosphate in neurons than in epithelial cells. 30 Our fi nding that high-dose valaciclovir increases the kinetics of viral clearance, but not expansion, supports the hypothesis that these antiviral drugs do not suppress the release of virions into the genital tract.
Our study had several strengths, including a rigorous cross-over design, which allowed for intraperson comparisons, and motivated participants who complied with intensive swabbing schedules. The high medication adherence rate, the inclusion of a three times daily drug regimen, and the similarity in episode frequency and duration across trials suggest that our fi ndings are not aff ected by the absorption kinetics of these antiviral drugs, but by their underlying mechanism of action. Additionally, we used a validated, highly sensitive and specifi c PCR assay, 22 minimising the likelihood of false-positive detection of HSV. Although the threshold copy number necessary or suffi cient for transmission has not been established, HSV transmission from culture-negative, PCR-positive secretions has been documented. 31 Additionally, the linear relation between log copy numbers and probability of viral replication in tissue media suggests that a threshold for infectivity is unlikely to be defi ned. 32 Ideally, these trials would have had several dose crossovers for each participant. 7 However, the intensity of taking swabs very frequently made this impracticablesuch a design would have necessitated intensive swabbing for nearly 150 days for each participant. Our study was not powered to compare shedding rates for diff erent antiviral doses between trials, because the cross-over design relied on comparison of the shedding rates within each person. The similarity in shedding rates for all doses shows the reproducibility of the results. However, in view of the diff erences in study design and population, we caution against direct comparisons between the antiviral doses of the three trials. We recruited people with clinically recognised disease who would be expected to have higher shedding rates in the trials of high-dose aciclovir and
